DEVICES TO MANAGE AORTIC VALVE DISEASE

Tuesday, March 11, 2025

8:00 AM – 10:00 AM ET

Moderator(s)

Kendra J. Grubb, MD

VP/CMO Structural Heart
Medtronic
Atlanta, Georgia, United States

Disclosure(s): Medtronic: Employee (Ongoing)
Toby Rogers, MD, PhD

Associate Professor of Medicine (Cardiology) and Scientific Lead for Structural Heart Disease
Georgetown University and MedStar Washington Hospital Center
Washington, District of Columbia, United States

Disclosure(s): Abbott: Consulting Fees (e.g., advisory boards) (Ongoing); Anteris: Consulting Fees (e.g., advisory boards) (Ongoing); Boston Scientific: Consulting Fees (e.g., advisory boards) (Ongoing); Edwards Lifesciences LLC: Consulting Fees (e.g., advisory boards) (Ongoing); Medtronic: Consulting Fees (e.g., advisory boards) (Ongoing); Transmural Systems, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing), Stock-privately held company (Ongoing)

Disclosure(s):

Kendra J. Grubb, MD: Medtronic: Employee (Ongoing)

Toby Rogers, MD, PhD: Abbott: Consulting Fees (e.g., advisory boards) (Ongoing); Anteris: Consulting Fees (e.g., advisory boards) (Ongoing); Boston Scientific: Consulting Fees (e.g., advisory boards) (Ongoing); Edwards Lifesciences LLC: Consulting Fees (e.g., advisory boards) (Ongoing); Medtronic: Consulting Fees (e.g., advisory boards) (Ongoing); Transmural Systems, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing), Stock-privately held company (Ongoing)